BlackThorn Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for neurobehavioral disorders. Their approach leveraged proprietary data, computational psychiatry, and brain imaging to identify and validate novel drug targets. BlackThorn aimed to create precision medicines for conditions like depression, anxiety, and other central nervous system disorders. In October 2020, BlackThorn Therapeutics was acquired by Neumora Therapeutics, a company launched with a similar mission to advance precision medicines for brain diseases. BlackThorn's assets and expertise were integrated into Neumora's platform.
The headquarters served as the central hub for research and development, clinical operations, corporate strategy, and administrative functions, driving the company's efforts in discovering and developing treatments for neurobehavioral disorders.
As a biotech company in a prominent innovation district, the facility likely featured advanced laboratory spaces for neuroscience research, drug discovery, and biomarker development, alongside modern office environments designed for collaboration.
The work culture at BlackThorn Therapeutics likely emphasized scientific rigor, innovation, collaboration between multidisciplinary teams (neuroscience, data science, clinical development), and a strong patient-centric focus, driven by the urgency to address unmet needs in mental health.
Its location in South San Francisco provided BlackThorn with access to a rich ecosystem of talent, research institutions, potential partners, and investors, crucial for a company in the competitive biopharmaceutical landscape.
As a clinical-stage biopharmaceutical company, BlackThorn Therapeutics' global presence was primarily related to its clinical trial activities. While its physical operations were centralized in South San Francisco, its research and development programs, particularly clinical trials for its drug candidates, may have involved collaborations with investigators and sites in multiple countries to ensure diverse patient populations and robust data collection.
400 Oyster Point Blvd, Suite 222
South San Francisco
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BlackThorn Therapeutics' leadership includes:
BlackThorn Therapeutics has been backed by several prominent investors over the years, including:
BlackThorn Therapeutics was acquired by Neumora Therapeutics in October 2020. Therefore, there have been no executive hires or exits for BlackThorn Therapeutics as an independent entity in the last 12 months. All significant leadership changes occurred around the time of the acquisition.
Discover the tools BlackThorn Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, BlackThorn Therapeutics likely used common corporate email formats based on its domain blackthornrx.com. As the company was acquired and the domain is no longer active for email, these formats are purely historical.
[first_initial][last]@blackthornrx.com
Format
jdoe@blackthornrx.com
Example
0%
Success rate
Neumora Therapeutics • October 13, 2020
Neumora Therapeutics announced its launch with a $400 million Series A financing and an additional $100 million in potential pharma R&D collaborations. Concurrently, Neumora acquired BlackThorn Therapeutics, integrating its pipeline, technology, and team to advance precision medicines for brain diseases....more
PR Newswire • January 7, 2020
BlackThorn Therapeutics reported positive topline results from its Phase 2 TACHYON study of BTRX-324, a kappa opioid receptor antagonist, in patients with major depressive disorder. The study met its primary endpoint, showing a statistically significant reduction in depressive symptoms....more
PR Newswire • July 17, 2018
BlackThorn Therapeutics secured $60 million in a Series B financing round. The funding was intended to advance its pipeline of novel, targeted therapeutics for neurobehavioral disorders, including its lead clinical candidate for major depressive disorder and its preclinical programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BlackThorn Therapeutics, are just a search away.